Your shopping cart is currently empty

Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylation of BCR/ABL and BCR/ABL-T315I, which promotes apoptosis. Vamotinib is used to study drug-resistant Philadelphia chromosome-positive (Ph+) leukaemia and Alzheimer's disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $108 | In Stock | In Stock | |
| 5 mg | $272 | In Stock | In Stock | |
| 10 mg | $446 | In Stock | In Stock | |
| 25 mg | $796 | In Stock | In Stock | |
| 50 mg | $1,090 | In Stock | In Stock | |
| 100 mg | $1,490 | - | In Stock | |
| 200 mg | $1,980 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $319 | In Stock | In Stock |
| Description | Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylation of BCR/ABL and BCR/ABL-T315I, which promotes apoptosis. Vamotinib is used to study drug-resistant Philadelphia chromosome-positive (Ph+) leukaemia and Alzheimer's disease. |
| Targets&IC50 | Abl (G250E):7.4 nM, BCR-ABL:0.49 nM, Abl (E255K):9.5 nM, Abl (F317I):2.0 nM, Abl (T315I):0.78 nM, Abl (Q252H):12 nM, Abl (Y253F):4.1 nM, Abl (H396P):1.0 nM |
| In vitro | Vamotinib (0-1000 nM) inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I in a dose-dependent manner. Additionally, it can suppress the growth of Ph+ patient-derived cell lines, including K562, KCL-22, SupB15, Tom-1, BV-173, as well as Ph+ PD-LTC cells with non-mutated resistance and T315I mutation[1]. |
| In vivo | In female BALB/cAnNRj-Foxn1nu mice (K562 nude mouse xenograft model), Vamotinib (25/40 mg/kg, oral gavage; 14 days) resulted in a 100% reduction in average tumor volume within 4 weeks. |
| Synonyms | PF-114 |
| Molecular Weight | 532.56 |
| Formula | C29H27F3N6O |
| Cas No. | 1416241-23-0 |
| Smiles | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3nnc4ccccn34)cc2C(F)(F)F)CC1 |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (56.33 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 2 mg/mL (3.76 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.